About Stratec Biomedical (ETR:SBS)
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Consumables segment develops and sells scientific materials, such as nucleic acid purification; and designs and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. STRATEC Biomedical AG also develops workflow software for networking several analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical Systems AG and changed its name to STRATEC Biomedical AG in April 2011. STRATEC Biomedical AG was founded in 1979 and is headquartered in Birkenfeld, Germany.
Industry, Sector and Symbol
Industry Medical Devices
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity26.35%
Return on Assets15.03%
Stratec Biomedical (ETR:SBS) Frequently Asked Questions
What is Stratec Biomedical's stock symbol?
Stratec Biomedical trades on the ETR under the ticker symbol "SBS."
What price target have analysts set for SBS?
6 brokers have issued twelve-month target prices for Stratec Biomedical's shares. Their forecasts range from €58.00 to €81.00. On average, they anticipate Stratec Biomedical's stock price to reach €66.23 in the next year. View Analyst Ratings for Stratec Biomedical.
Who are some of Stratec Biomedical's key competitors?
Some companies that are related to Stratec Biomedical include Draegerwerk AG & Co KGaA Preference Shares (DRW3), REVA Medical (RVA), Medica Group (MGP), Ellex Medical Lasers (ELXMF), Creo Medical Group (CREO), Hamilton Thorne (HTL), Kromek Group (KMK), Electromed (ELMD), Universal Biosensors (UBI), Advanced Oncotherapy (AVO), Protech Home Medical (PHM), MRI Interventions (MRIC), Surgical Innovations Group (SUN), NeuroOne Medical Tech (NMTC) and PetVivo (PETV).
Who are Stratec Biomedical's key executives?
Stratec Biomedical's management team includes the folowing people:
- Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 51)
- Dr. Robert Siegle, Director of Fin.s & HR and Member of Board of Management (Age 51)
- Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 51)
- Mr. Hermann Leistner, Founder & Advisor (Age 72)
- Sandra Eberle, Head of Investor Relations
Has Stratec Biomedical been receiving favorable news coverage?
Media stories about SBS stock have been trending somewhat positive on Monday, according to Accern. Accern scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stratec Biomedical earned a news sentiment score of 0.05 on Accern's scale. They also gave news headlines about the company an impact score of 45.36 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
What is Stratec Biomedical's stock price today?
One share of SBS stock can currently be purchased for approximately €72.00.
How big of a company is Stratec Biomedical?
Stratec Biomedical has a market capitalization of $833.27 million.
How can I contact Stratec Biomedical?
Stratec Biomedical's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160.
MarketBeat Community Rating for Stratec Biomedical (SBS)MarketBeat's community ratings are surveys of what our community members think about Stratec Biomedical and other stocks. Vote "Outperform" if you believe SBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBS will underperform the S&P 500 over the long term. You may vote once every thirty days.